Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821365 | 0.82 | TACR1 (0.46) | CYP19A1TACR1ALDH1A1TSHR | |
| N-Benzylmethylamine SCHEMBL5796449 | 0.80 | POLB (0.54) | CYP19A1SMN1; SMN2POLBPTGER4TP53 | |
| SCHEMBL4638842 | 0.79 | CYP19A1 (0.48) | CYP19A1TACR1POLBALDH1A1TSHR | |
| SCHEMBL4639523 | 0.78 | MAPT (0.46) | CYP19A1SMN1; SMN2POLBPTGER4TP53 | |
| SCHEMBL4638473 | 0.77 | ALDH1A1 (0.65) | CYP19A1SMN1; SMN2POLBPTGER4ALDH1A1 | |
| SCHEMBL9912521 | 0.76 | POLB (0.58) | POLBPTGER4ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL4638668 | 0.76 | POLB (0.51) | CYP19A1SMN1; SMN2POLBPTGER4TP53 | |
| SCHEMBL4706776 | 0.76 | ALDH1A1 (0.54) | CYP19A1SMN1; SMN2POLBPTGER4ALDH1A1 | |
| SCHEMBL4706773 | 0.74 | ALDH1A1 (0.49) | CYP19A1SMN1; SMN2POLBPTGER4ALDH1A1 | |
| SCHEMBL4707976 | 0.74 | CYP19A1 (0.57) | CYP19A1SMN1; SMN2POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CYP19A1 2652/4885SMN1; SMN2 2953/4885TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.